{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-008020","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.517014+00:00","generated_at":"2026-06-20T06:43:34.975120+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aprea Therapeutics appoints John Hamill as CFO, replacing Scott Coiante","bullets":["John Hamill appointed CFO effective Jan 30, 2023; succeeds Scott Coiante who remains through March 31.","Hamill brings over 30 years finance experience; previously CFO at Windtree Therapeutics, Trevena, NephroGenex.","Compensation: $420k base salary, 40% target bonus, $50k sign-on bonus (payable March 2024).","Equity grant: options for 539,758 shares (4-year vest) and RSUs for 269,879 shares (3-year vest).","Coiante receives 12 months base salary and health benefits under separation agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-008020","json":"https://secwatch.observer/filing/0001104659-23-008020.json","markdown":"https://secwatch.observer/filing/0001104659-23-008020.md","text":"https://secwatch.observer/filing/0001104659-23-008020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/tm234708d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:43:34.975120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70b64372bc","claim":"Scott Coiante departed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..","evidence_excerpt":"Mr. Hamill will replace Scott Coiante, who will step down from his role as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"a97ef6975d","claim":"John Hamill was appointed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..","evidence_excerpt":"Effective January 30, 2023 (the “Transition Date”), John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Aprea Therapeutics, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}